To the full analysis
Hangzhou Tigermed Consulting stock: growth
300347.SZHangzhou Tigermed Consulting reported $1.02B in revenue for fiscal 2025, up 3.5% on the prior year, up 16.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
34.1%
per year from 2009 to 2025, per share 28%
Earnings (Annual rate)
34.4%
per year from 2009 to 2025, per share 28.3%
Free cash flow (Annual rate)
34.3%
per year from 2009 to 2025, per share 28.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2009 | |
|---|---|---|---|
| Revenue | 16.4% | 21.7% | 34.1% |
| Revenue per share | 14.9% | 18.5% | 28.0% |
| Earnings | −12.7% | 19.0% | 34.4% |
| Earnings per share | −13.9% | 15.8% | 28.3% |
| Free cash flow | 1.4% | 24.8% | 34.3% |
| Free cash flow per share | 0.1% | 21.5% | 28.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2009 | $9.42M | $1.17M | $1.21M |
| 2010 | $18.42M | $4.76M | $2.74M |
| 2011 | $28.98M | $7.17M | $3.37M |
| 2012 | $38.14M | $10.16M | −$1.01M |
| 2013 | $50.47M | $14.11M | $5.95M |
| 2014 | $93.66M | $18.82M | $833.35K |
| 2015 | $143.52M | $23.44M | $14.79M |
| 2016 | $176.14M | $21.09M | $19.53M |
| 2017 | $252.99M | $45.14M | $40.34M |
| 2018 | $345.02M | $70.81M | $64.56M |
| 2019 | $420.4M | $126.22M | $63.68M |
| 2020 | $478.73M | $262.4M | $126.3M |
| 2021 | $781.84M | $431.02M | $158.24M |
| 2022 | $1.06B | $300.91M | $136.3M |
| 2023 | $1.11B | $303.65M | $125.47M |
| 2024 | $990.23M | $60.76M | $111.04M |
| 2025 | $1.02B | $133.15M | $135.52M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 16 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.